Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Clemens DL, Lee BY, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA.

PLoS One. 2019 May 10;14(5):e0215607. doi: 10.1371/journal.pone.0215607. eCollection 2019. Erratum in: PLoS One. 2019 May 30;14(5):e0217670.

2.

Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model.

Clemens DL, Lee BY, Plamthottam S, Tullius MV, Wang R, Yu CJ, Li Z, Dillon BJ, Zink JI, Horwitz MA.

ACS Infect Dis. 2019 Feb 8;5(2):281-291. doi: 10.1021/acsinfecdis.8b00268. Epub 2018 Dec 10.

PMID:
30480992
3.

Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.

Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ho CM, Horwitz MA.

PLoS One. 2018 Nov 14;13(11):e0207469. doi: 10.1371/journal.pone.0207469. eCollection 2018.

4.

Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.

Jia Q, Bowen R, Dillon BJ, Masleša-Galić S, Chang BT, Kaidi AC, Horwitz MA.

Sci Rep. 2018 May 3;8(1):7009. doi: 10.1038/s41598-018-24581-y.

5.

Acute Limb Ischemia in an 8-Year-Old Patient: A Case Report.

Erben Y, Miller SM, Sumpio BJ, Dillon BJ, Lee AI, Blume P, Sumpio BE, Mena-Hurtado C.

Ann Vasc Surg. 2018 Aug;51:327.e1-327.e8. doi: 10.1016/j.avsg.2018.02.012. Epub 2018 Apr 13.

PMID:
29655809
6.
7.

Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.

Stefanova D, Raychev A, Arezes J, Ruchala P, Gabayan V, Skurnik M, Dillon BJ, Horwitz MA, Ganz T, Bulut Y, Nemeth E.

Blood. 2017 Jul 20;130(3):245-257. doi: 10.1182/blood-2017-03-772715. Epub 2017 May 2.

8.

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.

Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA.

Nat Commun. 2017 Jan 24;8:14183. doi: 10.1038/ncomms14183.

9.

Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Jia Q, Bowen R, Lee BY, Dillon BJ, Masleša-Galić S, Horwitz MA.

Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28.

10.

Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice.

Lee BY, Li Z, Clemens DL, Dillon BJ, Hwang AA, Zink JI, Horwitz MA.

Small. 2016 Jul;12(27):3690-702. doi: 10.1002/smll.201600892. Epub 2016 Jun 1.

PMID:
27246117
11.

Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence.

Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, de la Torre JC, Kitchen SG, Horwitz MA, Bensinger SJ, Smale ST, Brooks DG.

PLoS Pathog. 2016 Jan 25;12(1):e1005356. doi: 10.1371/journal.ppat.1005356. eCollection 2016 Jan.

12.

Tuberculosis: pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice (Small 38/2015).

Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA.

Small. 2015 Oct;11(38):5065. doi: 10.1002/smll.201570235.

PMID:
26450161
13.

Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia.

Li Z, Clemens DL, Lee BY, Dillon BJ, Horwitz MA, Zink JI.

ACS Nano. 2015 Nov 24;9(11):10778-89. doi: 10.1021/acsnano.5b04306. Epub 2015 Oct 9.

PMID:
26435204
14.

pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.

Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA.

Small. 2015 Oct;11(38):5066-78. doi: 10.1002/smll.201500937. Epub 2015 Jul 20.

15.

Sonography-guided percutaneous liver biopsies in children.

Govender P, Jonas MM, Alomari AI, Padua HM, Dillon BJ, Landrigan-Ossar MF, Chaudry G.

AJR Am J Roentgenol. 2013 Sep;201(3):645-50. doi: 10.2214/AJR.12.9802.

PMID:
23971459
17.

Picture of the month-quiz case. Infantile Fibrosarcoma.

Prajapati V, Huang JT, Dillon BJ, Gellis SE, Liang MG.

Arch Pediatr Adolesc Med. 2012 Sep;166(9):863. doi: 10.1001/archpediatrics.2012.658. No abstract available.

PMID:
22945321
18.

Sclerotherapy of abdominal lymphatic malformations with doxycycline.

Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI.

J Vasc Interv Radiol. 2011 Oct;22(10):1431-5. doi: 10.1016/j.jvir.2011.06.021. Epub 2011 Aug 6.

PMID:
21821431
20.

Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2009 Jan 14;27(3):441-5. doi: 10.1016/j.vaccine.2008.10.058. Epub 2008 Nov 11.

21.

Delayed formation and rupture of a pseudoaneurysm after transjugular liver biopsy in a pediatric bone marrow transplant patient: imaging and endovascular treatment.

Dillon BJ, Alomari AI.

Cardiovasc Intervent Radiol. 2009 Mar;32(2):377-80. doi: 10.1007/s00270-008-9444-z. Epub 2008 Oct 4. No abstract available.

PMID:
18836768
22.

Angiographic demonstration of an aberrant abdominal umbilical artery in a patient with penoscrotal transposition and caudal regression.

Dillon BJ, Alomari AI.

Surg Radiol Anat. 2009 Mar;31(3):215-9. doi: 10.1007/s00276-008-0411-9. Epub 2008 Sep 16.

PMID:
18795221
23.

Lumbar artery pseudoaneurysm following inferior vena cava filter placement.

Dillon BJ, Alomari AI.

J Vasc Interv Radiol. 2008 Nov;19(11):1673-4. doi: 10.1016/j.jvir.2008.08.003. Epub 2008 Sep 12. No abstract available.

PMID:
18789724
24.

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA.

Infect Immun. 2008 Nov;76(11):5200-14. doi: 10.1128/IAI.00434-08. Epub 2008 Aug 25.

25.

A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2006 Mar 6;24(10):1593-600. Epub 2005 Oct 11.

26.

Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2006 Jan 23;24(4):443-51. Epub 2005 Aug 11.

28.

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.

Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA.

Cancer. 2004 Feb 15;100(4):826-33.

29.

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA.

Med Sci Monit. 2002 Jul;8(7):BR248-53.

PMID:
12118186
31.
32.

Survival of rats after temporary complete renal ischemia.

KOLETSKY S, DILLON BJ.

Proc Soc Exp Biol Med. 1949 Jan;70(1):14. No abstract available.

PMID:
18109712

Supplemental Content

Loading ...
Support Center